MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales
Ticker: MGRX · Form: 8-K · Filed: May 6, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
MANGOCEUTICALS, INC. signed a material deal creating debt and sold stock.
AI Summary
On April 28, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistered sales of equity securities and other events. The filing was made on May 6, 2025.
Why It Matters
This 8-K filing indicates MANGOCEUTICALS, INC. has entered into a significant agreement that creates a financial obligation and has also engaged in the sale of equity, which could impact its financial structure and shareholder base.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement creating a financial obligation and unregistered sales of equity, which can introduce financial and ownership structure risks.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- April 28, 2025 (date) — Date of Earliest Event Reported
- May 6, 2025 (date) — Filing Date
- 15110 N. Dallas Parkway , Suite 600 Dallas , Texas 75248 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did MANGOCEUTICALS, INC. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that it was entered into on April 28, 2025, and created a direct financial obligation.
What was the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 28, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on May 6, 2025.
What are the principal executive offices of MANGOCEUTICALS, INC.?
The principal executive offices of MANGOCEUTICALS, INC. are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
Besides the material agreement, what other significant events are mentioned in the filing?
The filing also mentions the creation of a direct financial obligation, unregistered sales of equity securities, and other events.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding MANGOCEUTICALS, INC. (MGRX).